The Best of Canadian Science and Technology
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has performed well both over the past year and during the current market … [Read more...] about Antibe Therapeutics is a “Top Pick” at Echelon Wealth
Echelon Wealth Partners analyst Douglas Loe said there’s no change to his investment thesis on clinical stage biotech name IMV (IMV Stock Quote, … [Read more...] about IMV has a massive upside, Echelon Wealth says
Stifel GMP analyst Justin Keywood likes what he sees so far from Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News TSX:GUD) as the … [Read more...] about Knight Therapeutics keeps “Buy” rating at Stifel GMP
The United States District Court for ruling in favour of the generic companies versus Amarin and its heart drug Vascepa has no bearing on HLS … [Read more...] about Vascepa litigation in the US will not affect HLS Therapeutics: Stifel
While COVID-19 will likely take a bite out of 2020 plans for Profound Medical (Profound Medical Stock Quote, Chart, News TSX:PRN), Raymond James … [Read more...] about Profound Medical has price target cut at Raymond James
Following the company's fourth quarter results, Stifel Canada analyst Justin Keywood has chopped his price target on Cipher Pharma (Cipher Pharma … [Read more...] about Cipher Pharma has price target cut at Stifel Canada
Its chart is one of the rare ones that doesn't look like a black diamond ski run, by analyst André Uddin says you can still make money off BELLUS … [Read more...] about BELLUS Health has more upside left, Mackie Research says
Following the company's fourth quarter results, Stifel Canada analyst Justin Keywood has maintained his "Buy" rating on HLS Therapeutics (HLS … [Read more...] about Buy HLS Therapeutics for a double, Stifel Canada says
There’s no change in analyst Douglas Loe’s valuation or development timelines for clinical-stage biotech name IMV (IMV Stock Quote, Chart, News … [Read more...] about A COVID-19 vaccine? Canada’s IMV might have the technology
Mackie Research analyst André Uddin is holding steady with Bellus Health (Bellus Health Stock Quote, Chart, News TSX:BLU) after clinical trial news … [Read more...] about Bellus Health is a double from here, says Mackie Research
